Yes thrombosis looks good

Table shows ABL dowregulated IL 1 , which the other publication teaches increases Hdl functionality . So we now see a MOA for ABL doing this. Crestor is noted in previous publication discussed here to do the same but thru a different MOA. These data may help account for great synergy we have seen in ABL with Crestor sub group RRR previous trial.

As for SOMAscans ; I would think that IF during BOM the Company has baseline as well as 1 & 2 year follow up SOMAscan data from some / all patients blood samples, the biomarkers signatures could be very obvious which patients are likely to be on ABL and which without these biomarkers signatures are not. Kind of like looking at a mass spectrograph printout. IF that were the case it would be very simple to compare the number of events in each group and draw some conclusions regarding likely success of BOM ? The SOMAscan data from the CKD trial led me to think of this possibility. All total speculation on my part and others probably way ahead of me and have different opinions.